-
-
-
-
-
-
-
Harrow re-launches VERKAZIA eye drops for pediatric eye condition
-
-
-
-
-
-
-
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
-
-
-
-
-
-
-
Harrow Announces Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Harrow Health (HROW) PT Raised to $70 at B.Riley
-
-
-
-
-
-
-
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
-
-
-
-
-
-
-
Harrow Launches VEVYE® Access for All
-
-
-
-
-
-
-
Harrow Announces Third Quarter 2024 Financial Results
-
1,171,064 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

